Skip to content
Screener

Net Income at other companies

Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.53B-0.1%
Amgen logo
AmgenAMGN
$2.38B+65.9%
AbbVie logo
AbbVieABBV
$3.62B+284%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
-$21.51M-39.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.36M-75.1%

Segments

By segment

See full
Reportable Segment-$15.15M-21.6%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$681.93M+1,826%
Enterprise value$621.3M-5,241%
P/S681.9×+670×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —Six Months Ended June 30, 2026 / $Six Months Ended June 30, 2026 / —Six Months Ended June 30, 2025 / $Six Months Ended June 30, 2025 / —
Interest income1,0298041,8321,416
Other expense(26)(230)(52)(155)
Total other income1,0035741,7801,261
Net loss$$(15,152)$$(12,458)$$(29,919)$$(26,160)
Unrealized (loss) gain on investments(63)1(69)(1)
Comprehensive loss$$(15,215)$$(12,457)$$(29,988)$$(26,161)
Net loss per share – basic and diluted$$(0.12)$$(0.24)$$(0.25)$$(0.51)
Weighted-average shares outstanding – basic and diluted129,779,29751,002,247121,675,47150,984,031

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s net income?
Shattuck Labs, Inc. (STTK) reported net income of -$15.15M in Q2 2026.
How has Shattuck Labs, Inc.'s net income changed year-over-year?
Shattuck Labs, Inc.'s net income decreased by 21.6% year-over-year, from -$12.46M to -$15.15M.
What is the long-term trend for Shattuck Labs, Inc.'s net income?
Over 3 years (2022 to 2025), Shattuck Labs, Inc.'s net income has grown at a -21.8% compound annual growth rate (CAGR), from -$101.95M to -$48.81M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Shattuck Labs, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude